AtriCure Enrolls First Patient in BoxX-NoAF Study
AtriCure (Nasdaq:ATRC) announced the enrollment of the first patient in its BoxX-NoAF clinical trial, evaluating its cardiac therapy technologies.
The BoxX-NoAF trial aims to define clinical practice and treatment guidelines for reducing post-operative AFib (POAF) and longer-term clinical AFib in high-risk cardiac surgery patients.
- The study investigates concomitant surgical ablation with left atrial appendage (LAA) management.
- Researchers seek to determine if this approach reduces the occurrence of new-onset AFib POAF compared to no treatment.
Anthony Rongione treated the first patient at Orlando Health Heart and Vascular Institute.
AtriCure hopes to establish new clinical practice and treatment guidelines through this trial.
Author's summary: AtriCure starts BoxX-NoAF trial to reduce AFib.
More News
- Eating ultra processed food could cause changes to the brain which could drive overeating
- Childcare assistance program money dispute in Rensselaer County
- Obituaries – Week of Oct. 27, 2025 - The Observer
- 2025 Victoria Derby Field & Betting Update: All Eyes on Observer - races.com.au
- Mike Brown is quickly reaching a crushing realization Knicks fans already knew
- MLB: Last time each team won the World Series
- Reneé Rapp Is Officially Heading Down Under Next Year - Star Observer
- In response to ‘The DMV: Humanity’s greatest crime against itself’
- Why Malaysia's Gig Workers Bill entrenches workers' dependency, not protection - Aliran
- Indonesia’s precariat protests call for stability